Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
ВИЧ-инфекция у беременных

Список литературы

  1. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984;224:500–503.
  2. Popovic M, Sarngadharan MG, Read E, et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984;224:497–500.
  3. Бартлетт Дж., Редфилд Р., Фам П., Мазус А.И. Клинические аспекты ВИЧ-инфекции. Российское издание 2013. М.: ГРАНАT; 2013: 696.
  4. Либман Г., Макадон Х.Дж. ВИЧ-инфекция. Пер. с англ. Мазус А.И., Бессараб Т.П., ред. М.: ГЭОТАР-Медиа; 2013: 560.
  5. Покровский В.В., ред. ВИЧ-инфекция и СПИД. Национальное руководство. М.: ГЭОТАР-Медиа; 2020: 696.
  6. Беляков Н.А., Рассохин В.В., Розенталь В.В., Огурцова С.В., Степанова Е.В., Мельникова Т.Н., Курганова Т.Ю., Азовцева О.В., Симакина О.Е. ТАА. Эпидемиология ВИЧ-инфекции. Место мониторинга, научных и дозорных наблюдений, моделирования и прогнозирования обстановки. ВИЧ-инфекция и иммуносупрессии, 2019, Том 11, № 2.
  7. Нечаева О.Б. Эпидемическая ситуация по ВИЧ-инфекции в России // 2019 г. – С.104.
  8. Прохорова О.Г. Развитие профилактики и медико-социальной помощи ВИЧ- инфицированным женщинам и детям Свердловской области /Прохорова О.Г., Ножкина.Н.В. // Вестник РГМУ. – 2013. - № 5-6. – С. 106-110.
  9. Современные рекомендации по диагностике и лечению ВИЧ -инфекции у детей и подростков /А.И. Мазус, М.В. Нагибина, А.С. Вербилова и др.:// Педиатрия. – 2019. - 98 (1): 151-158.
  10. Рекомендации по проведению профилактики передачи ВИЧ-инфекции от матери ребёнку /Д.В. Мелик-Гусейнов, А.Г. Коноплянников, А.И. Мазус, И.Е. и др.: Метод. рек. М.- 2017. – С. 8.
  11. P. Flynn, E. Abrams, M. Fowler. Prevention of mother-to-child HIV transmission in resource-limited settings.//2019 Oct.- https://www.uptodate.com/contents/prevention-of- mother-to-child-hiv-transmission-in-resource-limited-settings.
  12. Ellen R Cooper. Combination Antiretroviral Strategies for the Treatment of Pregnant HIV- 1–Infected Women and Prevention of Perinatal HIV-1 Transmission /R. Cooper et al // J Acquir Immune Defic Syndr.- 2002 Apr.- 29 (5): 484-494.
  13. F. Bustreo, R. Minghui. Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV and syphilis, 2nd edition. // WHO. - 2017. – 52: 4.
  14. G.М. Kassa. Mother-to-child transmission of HIV infection and its associated factors in Ethiopia: a systematic review and meta-analysis. // BMC Infect Dis. – 2018 – 18: 216.
  15. Самарина А.В. Реализация подходов по снижению перинатальной передачи ВИЧ /Самарина А.В., Беляков Н.А. // ВИЧ-инфекция и иммуносупрессии. – 2014. - 6(2): 7- 24.
  16. ВИЧ-инфекции. К классификация. Приложение к Инструкции по заполнению годовой формы государственного федерального статистического наблюдения № 61 “Сведения о контингентах больных ВИЧ-инфекцией”, утвержденной Приказом Минздравсоцразвития России от 61 "Сведения о контингентах больных ВИЧ-.
  17. American Academy of Pediatrics Committee on Pediatric AIDS. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics. 2008;122(5):1127-1134.Available at: http://www.ncbi.nlm.nih.gov/pubmed/18977995.
  18. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55 (RR-14):1-17; quiz CE11-14. Available at: http://www.ncbi.nlm.nih.gov/pubm.
  19. Chou R, Cantor AG, Zakher B, Bougatsos C. Screening for HIV in pregnant women: systematic review to update the 2005 U.S. Preventive services task force recommendation. Ann Intern Med. 2012;157(10):719-728. Available at: http://www.ncbi.nlm.nih.gov/pubmed/.
  20. U.S. Preventive Services Task Force. Screening for HIV: recommendation statement. 2013. Available at: http://www.uspreventiveservicestaskforce.org/uspstf/uspshivi.htm.
  21. American College of Obstetrics and Gynecology: Committee on Obstetric Practice, HIV Expert Work Group. ACOG committee opinion No. 752: prenatal and perinatal human immunodeficiency virus testing. Obstet Gynecol. 2018;132(3):e138-e142. Available at: https:
  22. Приказ департамента здравоохранения города Москвы от 17.08.2018 г. №563 «О дальнейшем совершенствовании мероприятий по профилактике перинатальной передачи ВИЧ-инфекции в медицинских организациях государственной системы здравоохранения города Москвы».
  23. Постановление Главного Государственного санитарного врача РФ от 21.07.2016 г. № 95 “О внесении изменений в СП 3.1.5.2826-10 Профилактика ВИЧ-инфекции.”
  24. Приказ Министерства здравоохранения РФ от 1 ноября 2012 г. N 572н "Об утверждении Порядка оказания медицинской помощи по профилю “акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий).”
  25. Smallwood M. et al. Evaluation of a rapid point of care test for detecting acute and established HIV infection, and examining the role of study quality on diagnostic accuracy: a Bayesian meta-analysis //PloS one. – 2016. – Т. 11. – №. 2. – С. e0149592.
  26. Yoo S. J. et al. Meta-analysis for the pooled sensitivity and specificity of anti-human immunodeficiency virus Ab rapid tests //The Korean Journal of Laboratory Medicine. – 2009. – Т. 29. – №. 4. – С. 345-352.
  27. Rosenberg N. E. et al. Recruiting male partners for couple HIV testing and counselling in Malawi’s option B+ programme: an unblinded randomised controlled trial //The lancet HIV. – 2015. – Т. 2. – №. 11. – С. e483-e491.
  28. Drake A. L. et al. Incident HIV during pregnancy and postpartum and risk of mother-to- child HIV transmission: a systematic review and meta-analysis //PLoS Med. – 2014. – Т. 11. – №. 2. – С. e1001608.
  29. Liao C, Golden WC, Anderson JR, Coleman JS. Missed opportunities for repeat HIV testing in pregnancy: implications for elimination of mother-to-child transmission in the United States. AIDS Patient Care STDS. 2017;31(1):20-26. Available at: https://ww.
  30. Thorne C., Newell M. L. Injecting drug use in pregnant HIV-infected women in Europe //Medycyna wieku rozwojowego. – 2006. – Т. 10. – №. 4. – С. 1005-1016.
  31. Shankaran S. et al. Impact of maternal substance use during pregnancy on childhood outcome //Seminars in Fetal and Neonatal Medicine. – WB Saunders, 2007. – Т. 12. – №. 2. – С. 143-150.
  32. Yoo, S. J., Sohn, Y.-H., Choi, S.-E., & Oh, H.-B. (2009). Meta-Analysis for the Pooled Sensitivity and Specificity of anti-Human Immunodeficiency Virus Ab Rapid Tests. The Korean Journal of Laboratory Medicine, 29(4), 345. doi:10.3343/kjlm.2009.29.4.345.
  33. Tan W. S. et al. Sensitivity of HIV rapid tests compared with fourth-generation enzyme immunoassays or HIV RNA tests //Aids. – 2016. – Т. 30. – №. 12. – С. 1951-1960.
  34. Sarınoğlu R. C. et al. Evaluation of Enzyme Immunoassay (EIA), Immunoblot and HIV RNA Polymerase Chain Reaction Test Results in the Diagnosis of Human Immunodeficiency Virus (HIV) Infection //Mikrobiyoloji bulteni. – 2019. – Т. 53. – №. 4. – С. 401-407.
  35. Wu S. et al. Prevalence of HIV Indeterminate Western Blot Tests and Follow-up of HIV Antibody Sero-Conversion in Southeastern China //Virologica Sinica. – 2019. – Т. 34. – №. 4. – С. 358-366.
  36. Zaaijer H. L. et al. Validation of a new immunoblot assay (LiaTek HIV III) for confirmation of human immunodeficiency virus infection //Transfusion. – 1998. – Т. 38. – №. 8. – С. 776-781.
  37. Hodgson I. et al. A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-infected pregnant and postpartum women //PloS one. – 2014. – Т. 9. – №. 11. – С. e111421.
  38. Yee LM, Miller ES, Statton A, et al. Sustainability of statewide rapid HIV testing in labor and delivery. AIDS Behav. 2018;22(2):538-544. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28986656.
  39. Scott RK, Crochet S, Huang CC. Universal rapid human immunodeficiency virus screening at delivery: a cost-effectiveness analysis. Infect Dis Obstet Gynecol. 2018;2018:6024698. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29731602.
  40. Branson BM, Owen SM, Wesolowski LG, et al. Laboratory testing for the diagnosis of HIV infection: updated recommendations. Centers for Disease Control and Prevention. 2014. Available at: https://www.medbox.org/laboratory-testing-for-the-diagnosis-of-hiv-i.
  41. Donovan M, Palumbo P. Diagnosis of HIV: challenges and strategies for HIV prevention and detection among pregnant women and their infants. Clin Perinatol. 2010;37(4):751- 763, viii. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21078448.
  42. Read JS, Committee on Pediatric AIDS, American Academy of Pediatrics. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics. 2007;120(6):e1547-1562. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18055670.
  43. Burgard M, Blanche S, Jasseron C, et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr. 2012;160(1):60-66 e61. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21.
  44. Coutsoudis A. et al. Breastfeeding and IIV International Transmission Study Group: Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta- analysis //J Infect Dis. – 2004. – Т. 189. – №. 12. – С. 2154-2166.
  45. White A. B. et al. Antiretroviral interventions for preventing breast milk transmission of HIV //Cochrane Database of Systematic Reviews. – 2014. – №. 10.
  46. Graybill L. A. et al. Incident HIV among pregnant and breast-feeding women in sub- Saharan Africa: a systematic review and meta-analysis //Aids. – 2020. – Т. 34. – №. 5. – С. 761-776.
  47. Babiker A. et al. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis //AIDS Research and Human Retroviruses. – 2000. – Т. 16. – №. 12. – С. 1123-1133.
  48. Fox M., McCarthy O., Over M. A novel approach to accounting for loss to follow-up when estimating the relationship between CD4 count at ART initiation and mortality //PLoS One. – 2013. – Т. 8. – №. 7. – С. e69300.
  49. Baillargeon J., Grady J., Borucki M. J. Immunological predictors of HIV-related survival //International journal of STD & AIDS. – 1999. – Т. 10. – №. 7. – С. 467-470.
  50. Kebede M., Zegeye D. T., Zeleke B. M. Predicting CD4 count changes among patients on antiretroviral treatment: Application of data mining techniques //Computer methods and programs in biomedicine. – 2017. – Т. 152. – С. 149-157.
  51. Stephan C. et al. Impact of baseline HIV‐1 RNA levels on initial highly active antiretroviral therapy outcome: a meta‐analysis of 12,370 patients in 21 clinical trials //HIV medicine. – 2013. – Т. 14. – №. 5. – С. 284-292.
  52. Al. MLM et. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, t // MMWR. Recomm. reports Morb. Mortal. Wkly. report. Recomm. reports/Centers Dis. Control. – 2009. – Т. 58. – №. RR-11. – С. 1.
  53. Hughes E. et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis //The Lancet Psychiatry. – 2016. – Т. 3. – №. 1. – С. 40-48.
  54. Chen J. J. et al. Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis //Hepatobiliary & Pancreatic Diseases International. – 2011. – Т. 10. – №. 2. – С. 122-127.
  55. Dianatinasab M. et al. Prevalence of tuberculosis in HIV-positive prisoners: a systematic review and meta-analysis //AIDS reviews. – 2018. – Т. 20. – №. 2. – С. 114-124.
  56. Wang TT, Xu Y, Li ZZ, Chen LZ. A meta-analysis of HIV seroprevalence in pregnant women with syphilis and the impact of syphilis infection on mother-to-child HIV transmission // Zhonghua Yu Fang Yi Xue Za Zhi. Zhonghua Yu Fang Yi Xue Za Zhi, 2016; 50, (11):. Pp. 1001–1007. doi: 10.3760/cma.j.issn.0253-9624.2016.11.015.
  57. Ong JJ, Baggaley RC, Wi TE, Tucker JD, Fu H, Smith MK, et al. Global Epidemiologic Characteristics of Sexually Transmitted Infections Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review and Meta-analysis // JAMA Netw. open. NLM (Medline), 2019; 2, (12):. Pp. e1917134. doi: 10.1001/jamanetworkopen.2019.17134.
  58. Wankah P. N., Tagny C. T., Mbanya D. N. S. Profile of blood cell abnormalities among antiretroviral therapy naïve HIV patients attending the Yaounde University Teaching Hospital, Cameroon //BMC hematology. – 2014. – Т. 14. – №. 1. – С. 15.
  59. Fellay, J., Ledergerber, B., Bernasconi, E., Furrer, H., Battegay, M., Hirschel, B., … Telenti, A. (2001). Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. The Lancet, 358(9290), 1322–1327. doi:10.1016/.
  60. Stainsby C. M. et al. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B* 5701 Screening as a Risk‐Mitigation Measure //Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. – 2019. – Т. 39. – №. 1. – С. 40-54.
  61. Tangamornsuksan W. et al. Association of HLA-B* 5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis //Journal of Pharmacy & Pharmaceutical Sciences. – 2015. – Т. 18. – №. 1. – С. 68-76.
  62. Luo X. et al. Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy //Journal of pharmacological sciences. – 2019. – Т. 139. – №. 4. – С. 275-279.
  63. Huntington S, Thorne C, Anderson J, et al. Does pregnancy increase the risk of ART- induced hepatotoxicity among HIV-positive women? J Int AIDS Soc. 2014;17(4 Suppl 3):19486. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25393995.
  64. Newell, M.-L., & Bunders, M. J. (2013). Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child. Current Opinion in HIV and AIDS, 8(5), 504–510. doi:10.1097/coh.0b013e3283632b88.
  65. Zash R. et al. Comparative safety of antiretroviral treatment regimens in pregnancy //JAMA pediatrics. – 2017. – Т. 171. – №. 10. – С. e172222-e172222.
  66. Biadgo B. et al. Gestational diabetes mellitus in HIV-infected pregnant women: A systematic review and meta-analysis //diabetes research and clinical practice. – 2019. – Т. 155. – С. 107800.
  67. Boender T. S. et al. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low-and middle-income countries: a systematic review and meta-analysis //Clinical Infectious Diseases. – 2015. – Т. 61. – №. 9. – С. 1453-1461.
  68. Wu J. et al. The prevalence of HIV drug resistance among treatment-failure individuals and treatment-naive individuals in China: a meta-analysis //Biomed Environ Sci. – 2014. – Т. 27. – №. 11. – С. 838-871.
  69. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г., Шахгильдян В.И., Козырина Н.В., Буравцова В.В., Нарсия Р.С., Покровская А.В., Ефремова О.С., Коннов В.В., Куимова У.А., Попова А.А., Хохлова О.Н., Воронин Е.Е., Афонина Л.
  70. The European AIDS Clinical Society (EACS) Guidelines Version 10.0 November 2019. https://www.eacsociety.org/files/eacs_gudelines_2019_rus.pdf.
  71. HIV 2015/2016. Edited Hoffmann C., Rockstroh J.K. Medizin Fokus Verlag, Hamburg, 2015. 776с. https://hivbook.com/.
  72. Amniocentesis and Women with Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus. (2003). Journal of Obstetrics and Gynaecology Canada, 25(2), 145–148. doi:10.1016/s1701-2163(16)30211-0 e.
  73. Simões M. et al. Amniocentesis in HIV pregnant women: 16 years of experience //Infectious diseases in obstetrics and gynecology. – 2013. – Т. 2013.
  74. Floridia M. et al. Amniocentesis and chorionic villus sampling in HIV‐infected pregnant women: a multicentre case series //BJOG: An International Journal of Obstetrics & Gynaecology. – 2017. – Т. 124. – №. 8. – С. 1218-1223.
  75. Floridia M, Masuelli G, Meloni A, et al. Amniocentesis and chorionic villus sampling in HIV-infected pregnant women: a multicentre case series. BJOG. 2017;124(8):1218-1223. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27319948.
  76. Nduka C. U. et al. Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysis //Journal of Human Hypertension. – 2016. – Т. 30. – №. 6. – С. 355-362.
  77. Patel N. et al. Frequency of electrocardiogram testing among HIV‐infected patients at risk for medication‐induced QTc prolongation //HIV medicine. – 2013. – Т. 14. – №. 8. – С. 463-471.
  78. Van Hoving D. J. et al. Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV‐positive individuals //Cochrane Database of Systematic Reviews. – 2019. – №. 9.
  79. Centers for Disease Control and Prevention. Guidelines for vaccinating pregnant women. 2017. Available at: https://www.cdc.gov/vaccines/pregnancy/hcp/guidelines.html.).
  80. Madhi S. A. et al. Influenza vaccination of pregnant women and protection of their infants //New England Journal of Medicine. – 2014. – Т. 371. – №. 10. – С. 918-931.
  81. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-100. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24311479.
  82. Mohseni H, Kiran A, Khorshidi R, Rahimi K. Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study.Eur Heart J. 2017; 38:326–333. doi: 10.1093/eurheartj/ehw411.
  83. Ciesla J. A., Roberts J. E. Meta-analysis of the relationship between HIV infection and risk for depressive disorders //American Journal of Psychiatry. – 2001. – Т. 158. – №. 5. – С. 725-730.
  84. Ssentongo P. Prevalence and incidence of new-onset seizures and epilepsy in patients with human immunodeficiency virus (HIV): Systematic review and meta-analysis //Epilepsy & Behavior. – 2019. – Т. 93. – С. 49-55.
  85. O’connor E. E., Zeffiro T. A., Zeffiro T. A. Brain structural changes following HIV infection: meta-analysis //American Journal of Neuroradiology. – 2018. – Т. 39. – №. 1. – С. 54-62.
  86. Skoraszewski M. J., Ball J. D., Mikulka P. Neuropsychological functioning of HIV-infected males //Journal of Clinical and Experimental Neuropsychology. – 1991. – Т. 13. – №. 2. – С. 278-290.
  87. Crepaz N. et al. Meta-analysis of cognitive-behavioral interventions on HIV-positive persons’ mental health and immune functioning //Health Psychology. – 2008. – Т. 27. – №. 1. – С. 4.
  88. Sin N. L., DiMatteo M. R. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis //Annals of Behavioral Medicine. – 2014. – Т. 47. – №. 3. – С. 259-269.
  89. Luo Z. et al. Lifetime prevalence of suicidal ideation among men who have sex with men: a meta-analysis //BMC psychiatry. – 2017. – Т. 17. – №. 1. – С. 1-9.
  90. Барлетт Д., Галлант Д. Фам П. Клинические аспекты ВИЧ-инфекции. 2009-2010. М.: Р.Валент, 2010. 490с.
  91. Покровский В.В., ред. ВИЧ-инфекция и СПИД. Клинические рекомендации. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2010. 186 с.
  92. Методические рекомендации МР 3.1.5.0076/1-13 от 20.08.2013 г. «До- и послетестовое консультирование как профилактика передачи ВИЧ».
  93. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26192873.).
  94. Федеральный закон от 21 ноября 2011 г. N 323-ФЗ “Об основах охраны здоровья граждан в Российской Федерации”, Федеральный закон от 29.11.2010 № 326-ФЗ “Об обязательном медицинском страховании в Российской Федерации.”
  95. Wedi C. O. O. et al. Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis //The lancet HIV. – 2016. – Т. 3. – №. 1. – С. e33-e48.
  96. Mirochnick, M., & Capparelli, E. (2004). Pharmacokinetics of Antiretrovirals in Pregnant Women. Clinical Pharmacokinetics, 43(15), 1071–1087. doi:10.2165/00003088- 200443150-00002.
  97. Raffe SF, Savage C, Perry LA, et al. The management of HIV in pregnancy: a 10-year experience. Eur J Obstet Gynecol Reprod Biol. 2017;210:310-313. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28110176.).
  98. Watts DH. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep. 2007;4(3):135-140. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17883999.
  99. Sturt A. S., Dokubo E. K., Sint T. T. Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women //Cochrane Database of Systematic Reviews. – 2010. – №. 3.
  100. Ioannidis J. P. A. et al. Maternal viral load and rate of disease progression among vertically HIV-1-infected children: an international meta-analysis //Aids. – 2004. – Т. 18. – №. 1. – С. 99-108.
  101. de Martino M. et al. Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1? //Clinical infectious diseases. – 2009. – Т. 48. – №. 9. – С. 1310-1317.
  102. Mandelbrot L. et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception //Clinical Infectious Diseases. – 2015. – Т. 61. – №. 11. – С. 1715-1725.
  103. Veroniki A. A. et al. Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta- analysis including different study designs //PloS one. – 2018. – Т. 13. – №. 6. .
  104. Ford N. et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis //Aids. – 2014. – Т. 28. – С. S123-S131.
  105. van De Ven N. S. et al. Analysis of pharmacovigilance databases for dolutegravir safety in pregnancy //Clinical Infectious Diseases. – 2020. – Т. 70. – №. 12. – С. 2599-2606.
  106. Perinatal H. I. V. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1- Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. – 2021.
  107. drew Hill A. et al. Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review //Journal of virus eradication. – 2018. – Т. 4. – №. 2. – С. 66- 71.
  108. Ford N. et al. Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis //Aids. – 2013. – Т. 27. – №. 7. – С. 1135-1143.
  109. de Ruiter A, Taylor GP, Clayden P, et al. British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). HIV Med. 2014;15 Suppl 4:1-77. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25604045.
  110. British HIV Association. British HIV association guidelines for the management of HIV in pregnancy and postpartum 2018. HIV Med. 2019;20 Suppl 3:s2-s85. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30869192.
  111. European Collaborative Study, Swiss Mother Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14(18):2913-2920. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11398741.
  112. Rudin C, Spaenhauer A, Keiser O, et al. Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data. HIV Med. 2011;12(4):228-235. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20726902.
  113. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2019. Available at: AdultandAdolescentGL.pdf. AdultandAdolescentGL.pdf.
  114. British HIV Association. BHIVA guidelines on the management of HIV in pregnancy and postpartum 2018 (2019 interim update). 2019. Available at: https://www.bhiva.org/pregnancy-guidelines.
  115. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362(24):2271-2281. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20554982.
  116. Williams PL, Hazra R, Van Dyke RB, et al. Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design. AIDS. 2016;30(1):133-144. Available at: https://www.ncbi.nlm.nih.gov/pubme.
  117. Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol. 2008;66(2):179-195. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18537960.
  118. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the panel on clinical practices for treatment of HIV infection convened by the Department of Health and Human Services (DHHS). July 14, 2016. http://www.
  119. Pediatric HIV/AIDS Cohort Study. Surveillance monitor of ART toxitities (SMARTT) study annual administrative report. 2017. Available at: https://phacsstudy.org/cms_uploads/Latest%20Documents/SMARTT_Annual_Administra tive_Report_Apr2017_web.pdf.
  120. Siemieniuk RA, Foroutan F, Mirza R, et al. Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis. BMJ Open. 2017;7(9):e019022. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28893758.
  121. Fowler MG, Qin M, Fiscus SA, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375(18):1726-1737. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27806243.
  122. Cohen M. S. et al. Antiretroviral therapy for the prevention of HIV-1 transmission //New England Journal of Medicine. – 2016. – Т. 375. – №. 9. – С. 830-839.
  123. Rodger A. J. et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy //Jama. – 2016. – Т. 316. – №. 2. – С. 171-181.
  124. Humphrey J. H. et al. Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study //Bmj. – 2010. – Т. 341.
  125. Приказ Министерства здравоохранения РФ от 19.12.2003 г. №606 «Об утверждении инструкции по профилактике передачи ВИЧ-инфекции от матери ребенку и образца информированного согласия на проведение химиопрофилактики ВИЧ».
  126. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd003510.
  127. Calvert C., Ronsmans C. HIV and the risk of direct obstetric complications: a systematic review and meta-analysis //PloS one. – 2013. – Т. 8. – №. 10. – С. e74848.
  128. Shapiro DE, Sperling RS, Mandelbrot L, Britto P, Cunningham BE. Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis. Pediatric AIDS Clinical Trials Group protocol 076 Study Group. Obstet Gyneco.
  129. Peters H. et al. Duration of ruptured membranes and mother‐to‐child HIV transmission: a prospective population‐based surveillance study //BJOG: An International Journal of Obstetrics & Gynaecology. – 2016. – Т. 123. – №. 6. – С. 975-981.
  130. Minkoff H. et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus //American journal of obstetrics and gynecology. – 1995. – Т. 173. – №. 2. – С. 585-589.
  131. Cotter A. M. et al. Duration of membrane rupture and risk of perinatal transmission of HIV- 1 in the era of combination antiretroviral therapy //American journal of obstetrics and gynecology. – 2012. – Т. 207. – №. 6. – С. 482. e1-482. e5.
  132. Brocklehurst P. Interventions for reducing the risk of mother‐to‐child transmission of HIV infection //Cochrane Database of Systematic Reviews. – 2002. – №. 1.
  133. The Mode of Delivery and the Risk of Vertical Transmission of Human Immunodeficiency Virus Type 1 — A Meta-Analysis of 15 Prospective Cohort Studies. (1999). New England Journal of Medicine, 340(13), 977–987. doi:10.1056/nejm199904013401301.
  134. Aebi-Popp K. et al. Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery //JAIDS Journal of Acquired Immune Deficiency Syndromes. – 2013. – Т. 64. – №. 1. – С. 58-65.
  135. Villari P. et al. Cesarean section to reduce perinatal transmission of human immunodeficiency virus. A metaanalysis. – 1993.
  136. Kennedy C. E. et al. Elective cesarean section for women living with HIV: a systematic review of risks and benefits //AIDS (London, England). – 2017. – Т. 31. – №. 11. – С. 1579.
  137. Kourtis AP, Ellington S, Pazol K, Flowers L, Haddad L, Jamieson DJ. Complications of cesarean deliveries among HIV-infected women in the United States. AIDS. 2014;28(17):2609-2618. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25574961.
  138. Spaulding A. B. et al. Linking family planning with HIV/AIDS interventions: a systematic review of the evidence //Aids. – 2009. – Т. 23. – С. S79-S88.
  139. Wilcher R. et al. Integration of family planning into HIV services: a synthesis of recent evidence //Aids. – 2013. – Т. 27. – С. S65-S75.
  140. Lopez L. M. et al. Behavioral interventions for improving contraceptive use among women living with HIV //Cochrane Database of Systematic Reviews. – 2016. – №. 8.
  141. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis. 2008;35(11):946-959. Available.
  142. Anderson BL, Firnhaber C, Liu T, et al. Effect of trichomoniasis therapy on genital HIV viral burden among African women. Sex Transm Dis. 2012;39(8):638-642. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22797689.
  143. Blish CA, McClelland RS, Richardson BA, et al. Genital inflammation predicts HIV-1 shedding independent of plasma viral load and systemic inflammation. J Acquir Immune Defic Syndr. 2012;61(4):436-440. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22878.
  144. Homans J, Christensen S, Stiller T, et al. Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. J Acquir Immune Defic Syndr. 2012;60(1):99-110. Available at: http://www.ncbi.nlm.nih.go.
  145. Wall KM, Kilembe W, Vwalika B, et al. Risk of heterosexual HIV transmission attributable to sexually transmitted infections and non-specific genital inflammation in Zambian discordant couples, 1994-2012. Int J Epidemiol. 2017;46(5):1593-1606. Available at.
  146. Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner Is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171-181. Available at: https://www.nc.
  147. Becquet R, Ekouevi DK, Arrive E, et al. Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis. 2009;49(12):1936.
  148. Tubiana R, Le Chenadec J, Rouzioux C, et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/mL at delivery: a case- control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis.
  149. Zafer M., Horvath H., Mmeje O., van der Poel S., Semprini A., Rutherford G. et al. Effectiveness of semen washing to prevent HIV transmission and assist pregnancy in HIV- discordant couples: a systematic review and meta-analysis. Fertil Steril. 2016;105(3).
  150. Приказ 803н от 31 июля 2020 года «О порядке использования вспомогательных репродуктивных технологий, противопоказаниях и ограничениях к их применению».
  151. Barnes A. et al. Efficacy and safety of intrauterine insemination and assisted reproductive technology in populations serodiscordant for human immunodeficiency virus: a systematic review and meta-analysis //Fertility and sterility. – 2014. – Т. 102. – №. .
  152. Chaabane S. et al. Ovarian stimulation, intrauterine insemination, multiple pregnancy and major congenital malformations: a systematic review and meta-analysis-The ART_Rev Study //Current drug safety. – 2016. – Т. 11. – №. 3. – С. 222-261.
  153. Kato S. et al. Complete removal of HIV-1 RNA and proviral DNA from semen by the swim- up method: assisted reproduction technique using spermatozoa free from HIV-1 //Aids. – 2006. – Т. 20. – №. 7. – С. 967-973.
  154. Guidelines for risk reduction when handling gametes from infectious patients seeking assisted reproductive technologies//Sangita K Jindal a,*, Richard G Rawlins b, Charles H Muller c, Erma Z Drobnis d. Reproductive BioMedicine Online (2016) http://dx.doi.
  155. Dare M. R. et al. Single or multiple embryo transfer following in vitro fertilisation for improved neonatal outcome: a systematic review of the literature //Australian and New Zealand journal of obstetrics and gynaecology. – 2004. – Т. 44. – №. 4. – С. 28.
  156. Marjan M.C., Steenvoorden, M. Cornelissen, E. Leeuwen, N. M. Schuurman, H. F. Egberink, B.S. BenBerkhout, Fulcovan der Veen, S. Repping. Integration of immunodeficiency virus in oocytes via intracytoplasmic injection: possible but extremely unlikely// Fer.
  157. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol. 1997;176(2):478-489. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9065202.
  158. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 January 1989–31 January 2019. Wilmington, NC: Registry Coordinating Center. 2019. Available at: http://www.apregistry.com.
  159. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43(15):1071-1087. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15568888.
  160. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2018. Available at: AdultandAdolescentGL.pdf.
  161. Schalkwijk S, Colbers A, Konopnicki D, et al. The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women. AIDS. 2016;30(8):1239-1244. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26836789.
  162. Vannappagari V, Koram N, Albano J, Tilson H, Gee C. Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the antiretroviral pregnancy registry. J Acquir Immune Defic Syndr. 2015;68(3):359-364. Available a.
  163. Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother. 2011;55(12):5914-5922. Available at: htt.
  164. Colbers AP, Hawkins DA, Gingelmaier A, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS. 2013;27(5):739- 748. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23169329.
  165. И.Е. Шохин, Ю.В. Медведев, Т.Н. Комаров, О.В. Климова, Б.В. Бровченко. Изучение кинетики растворения инновационного антиретровирусного препарата Никавир® и его фиксированной комбинации с ламивудином (Фосфаладин®) // Разработка и регистрация лекарственных .
  166. Momper J, Best B, Wang J, et al. Tenofovir alafenamide pharmacokinetics with and without cobicistat in pregnancy. Presented at: 22nd International AIDS Conference. 2018. Amsterdam, Netherlands.
  167. Best BM, Burchett S, Li H, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015;16(8):502-511. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25959631.
  168. 182. O’Sullivan MJ, Boyer PJ, Scott GBea. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials .
  169. Badell ML, Sheth AN, Momplaisir F, et al. A multicenter analysis of elvitegravir use during pregnancy on HIV viral suppression and perinatal outcomes. Open Forum Infect Dis. 2019;6(4):ofz129. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31037241.
  170. Capparelli EV, Aweeka F, Hitti J, et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008;9(4):214-220. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18366444.
  171. Eley T, Bertz R, Hardy H, Burger D. Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review. Antivir Ther. 2013;18(3):361-375. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23676668.
  172. Stek A, Best BM, Wang J, et al. Pharmacokinetics of once versus twice daily darunavir In pregnant HIV-infected women. J Acquir Immune Defic Syndr. 2015. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25950206.
  173. Khuong-Josses MA, Azerad D, Boussairi A, Ekoukou D. Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women. HIV-Clin Trials. 2007;8(4):254-255. Available at: http://www.ncbi.nlm.nih.gov/pubm.
  174. Colbers A, Best B, Schalkwijk S, et al. Maraviroc pharmacokinetics in HIV-1-infected pregnant women. Clin Infect Dis. 2015;61(10):1582-1589. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26202768.
  175. Waitt C, Orrell C, Walimbwa S, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS Med. 2019;16(9):e1002895. Available at: https://www.ncbi.nlm.nih.gov/pu.
  176. Floridia M, Pinnetti C, Ravizza M, et al. Brief report: abacavir/lamivudine and tenofovir/emtricitabine in pregnant women with HIV: laboratory and clinical outcomes in an observational national study. J Acquir Immune Defic Syndr. 2018;78(1):99-104. Availa.
  177. Sousa-Pinto B, Pinto-Ramos J, Correia C, et al. Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA- B*57:01. J Allergy Clin Immunol. 2015;136(4):
  178. Efavirenz [package insert]. Food and Drug Administration. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020972s057,021360s045lbl.pdf.
  179. Rasi V, Cortina-Borja M, Peters H, Sconza R, Thorne C. Brief report: surveillance of congenital anomalies after exposure to raltegravir or elvitegravir during pregnancy in the United Kingdom and Ireland, 2008-2018. J Acquir Immune Defic Syndr. 2019;80(3):
  180. Watts DH, Stek A, Best BM, et al. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014;67(4):375-381. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25162818.
  181. Blonk M, Colbers A, Hidalgo-Tenorio C, et al. Raltegravir in HIV-1 infected pregnant women: pharmacokinetics, safety and efficacy. Clin Infect Dis. 2015. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25944344.
  182. Maliakkal A, Walmsley S, Tseng A. Critical review: review of the efficacy, safety, and pharmacokinetics of raltegravir in pregnancy. J Acquir Immune Defic Syndr. 2016;72(2):153-161. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27183177.
  183. Cecchini DM, Martinez MG, Morganti LM, Rodriguez CG. Antiretroviral therapy containing raltegravir to prevent mother-to-child transmission of HIV in infected pregnant women. Infect Dis Rep. 2017;9(2):7017. Available at: https://www.ncbi.nlm.nih.gov/pubmed.
  184. Colbers A, Molto J, Ivanovic J, et al. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women. J Antimicrob Chemother. 2015;70(2):534-542. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25326090.
  185. Schalkwijk S, Ter Heine R, Colbers A, et al. Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. J Antimicrob Chemother. 2019. Available at: https://www.ncbi.nlm.nih.gov/pubmed/3.
  186. Rough K, Sun JW, Seage GR, 3rd, et al. Zidovudine use in pregnancy and congenital malformations. AIDS. 2017;31(12):1733-1743. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28537936.
  187. Van Dyke RB, Chadwick EG, Hazra R, Williams PL, Seage GR, 3rd. The PHACS SMARTT study: assessment of the safety of in utero exposure to antiretroviral drugs. Front Immunol. 2016;7:199. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27242802.
  188. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018;379(10):979-981 Available at: https://www.ncbi.nlm.nih.gov/pubmed/30037297.
  189. Lewis JM, Railton E, Riordan A, Khoo S, Chaponda M. Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing. AIDS. 2016;30(8):1313-1315. Available at: https://www.ncbi.nl.
  190. Mulligan N, Best BM, Wang J, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018;32(6):729-737. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29369162.
  191. Conradie F, Zorrilla C, Josipovic D, et al. Safety and exposure of once-daily ritonavir- boosted atazanavir in HIV-infected pregnant women. HIV Med. 2011;12(9):570-579. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21569187.
  192. Le MP, Mandelbrot L, Descamps D, et al. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women. Antivir Ther. 2015;20(5):507-13. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25599.
  193. Ramautarsing RA, van der Lugt J, Gorowara M, et al. Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. AIDS. 2011;25(10):1299-1303. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2151.
  194. Salem AH, Jones AK, Santini-Oliveira M, et al. No need for lopinavir dose adjustment during pregnancy: a population pharmacokinetic and exposure-response analysis in pregnant and nonpregnant HIV-infected subjects. Antimicrob Agents Chemother. 2016;60(1):4.
  195. Bouillon-Pichault M, Jullien V, Azria E, et al. Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J Antimicrob Chemother. 2009;63(6):1223-1232. Available at: http:
  196. Bonafe SM, Costa DA, Vaz MJ, et al. A randomized controlled trial to assess safety, tolerability, and antepartum viral load with increased lopinavir/ritonavir dosage in pregnancy. AIDS Patient Care STDS. 2013;27(11):589-595. Available at: http://www.ncbi.
  197. Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr. 2012;59(3):245- 252. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22083071.
  198. Kreitchmann R, Schalkwijk S, Best B, et al. Efavirenz pharmacokinetics during pregnancy and infant washout. Antivir Ther. 2019;24(2):95-103. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30530925.
  199. Williams J, Mai CT, Mulinare J, et al. Updated estimates of neural tube defects prevented by mandatory folic Acid fortification—United States, 1995–2011. MMWR Morb Mortal Wkly Rep. 2015;64(1):1-5. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25590678.
  200. Osiyemi O, Yasin S, Zorrilla C, et al. Pharmacokinetics, antiviral activity, and safety of rilpivirine in pregnant women with HIV-1 infection: results of a Phase 3b, multicenter, open-label study. Infect Dis Ther. 2018;7(1):147-159. Available at: https://.
  201. Tran AH, Best BM, Stek A, et al. Pharmacokinetics of rilpivirine in HIV-infected pregnant women. J Acquir Immune Defic Syndr. 2016;72(3):289-296. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26918544.
  202. Schalkwijk S, Colbers A, Konopnicki D, et al. Lowered rilpivirine exposure during third trimester of pregnancy in HIV-1-positive women. Clin Infect Dis. 2017;65(8):1335-1341. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28595298.
  203. Ramgopal M, Osiyemi O, Zorrilla C, et al. Pharmacokinetics of total and unbound etravirine in HIV-1-infected pregnant women. J Acquir Immune Defic Syndr. 2016;73(3):268-274. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27159225.
  204. Mulligan N, Schalkwijk S, Best BM, et al. Etravirine pharmacokinetics in HIV-infected pregnant women. Front Pharmacol. 2016;7:239. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27540363.
  205. Benaboud S, Ekouevi DK, Urien S, et al. Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. Antimicrob Agents Chemother. 2011;55(1):331-337. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20956588.
  206. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med. 2006;7(4):255-260. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16630038.
  207. Ford N, Calmy A, Andrieux-Meyer I, Hargreaves S, Mills EJ, Shubber Z. Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. AIDS. 2013. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23299174.
  208. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis. 2003;23(2):173-182. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12800070.
  209. Sued O, Lattner J, Gun A, et al. Use of darunavir and enfuvirtide in a pregnant woman. Int J STD AIDS. 2008;19(12):866-867. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19050223.
  210. Shust GF, Jao J, Rodriguez-Caprio G, et al. Salvage regimens containing darunavir, etravirine, raltegravir, or enfuvirtide in highly treatment-experienced perinatally infected pregnant women. J Pediatric Infect Dis Soc. 2014;3(3):246-250. Available a.
  211. Bicitegravir/emtricitabine/tenofovir alafendamide fumarate (Biktarvy) [package insert]. Food and Drug Administration. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210251s006lbl.pdf.
  212. Doravirine [package insert]. Food and Drug Administration. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210806s003lbl.pdf.
  213. Momper J, Best BM, Wang J, et al. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018;32(17):2507-2516. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30134297.
  214. Boyd SD, Sampson MR, Viswanathan P, Struble KA, Arya V, Sherwat AI. Cobicistat- containing antiretroviral regimens are not recommended during pregnancy: viewpoint. AIDS. 2019;33(6):1089-1093. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30946163.
  215. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. // N. Engl. J. Med. — 1998. — Vol. 338. — P. 853-860.
  216. Применение антиретровирусных препаратов в комплексе мер, направленных на профилактику передачи ВИЧ от матери ребенку. Клинические рекомендации (протокол лечения). Эпидемиол. и инфекц. болезни. Актуал. вопр. 2015; 3 (приложение). 24 с.
  217. Department of Health and Human Services. Recommendations for Use of Antiretroviral Drugs in PregnantHIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, 2016 http://aidsinfo.nih.gov/guidelines Perinatal HIV Transmission in the United States, 2016 http://aidsinfo.nih.gov/guidelines.
  218. APRegistry. The Antiretrovial Pregnancy Registry Interim Report: 01 January 1989 Through 31 January 2020. Wilmington, NC. Issued: June. 2020.
  219. Kityo C, Hagins D, Koeing E, et al. Longer-term (96-week) Efficacy and Safety of Switching to Bictegravir, Emtricitabine and Tenofovir Alafenamide (B/F/TAF) in Women [Presentation]. Paper presented at: 10th IAS Conference on HIV Science (IAS 2019); 21- 24 July, 2019; Mexico City, Mexico.
  220. Orkin C, Ajana F, Kityo C, et al. Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide vs Comparators in Women and Girls: an Analysis of 5 Clinical Trials [Presentation]. Paper presented at: EACS; 06-09 November, 2019; Basel, Switzerland.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу